Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Oak hill bio has raised $32.5M in total funding. The most recent round was Series A. The last funding was announced in June 2026.
Oak hill bio's investors include Balyasny Asset Management, Janus Henderson Investors, venBio Partners, KCap Biotechnology Fund.
Oak hill bio is headquartered in Altrincham, United Kingdom.
Oak hill bio is a clinical-stage rare disease therapeutics company developing life-changing medicines.
Oak hill bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oak hill bio — Funding & Investors." VCBacked, June 1, 2026, https://www.vcbacked.co/company/oak-hill-bio. Accessed October 8, 2026.
VCBacked. (2026). Oak hill bio — Funding & Investors. Retrieved October 8, 2026, from https://www.vcbacked.co/company/oak-hill-bio
{{cite web |title=Oak hill bio — Funding & Investors |url=https://www.vcbacked.co/company/oak-hill-bio |website=VCBacked |access-date=October 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated